Difference between revisions of "Template:Major side effects of bicalutamide alone"

From blackwiki
Jump to navigation Jump to search
imported>Medgirl131
Line 20: Line 20:
 
| [[Hepato-biliary disorder]]s || • [[Hepatotoxicity|Liver toxicity]]<sup>d</sup>
 
| [[Hepato-biliary disorder]]s || • [[Hepatotoxicity|Liver toxicity]]<sup>d</sup>
 
|- class="sortbottom"
 
|- class="sortbottom"
| colspan="3" style="width: 1px;" | {{Hidden | <noinclude>expanded = true |</noinclude> header = Footnotes and sources | content = <sup>a</sup> = Incidence of breast changes of up to 80 to 90%. Mild-to-moderate in 90% of cases. Incidence greatly decreased in combination with castration.<br /><sup>b</sup> = Elevated liver enzymes rarely severe and usually transient, resolving or improving with continued therapy or with discontinuation. Incidence of 3.4% relative to 1.9% for placebo in a high-dose (150&nbsp;mg/day) 4,000-patient trial.<br /><sup>c</sup> = Six case reports of interstitial lung disease published (as of 2016). Incidence of 0.01% (12 patients) in an 87,000-patient cohort.<br /><sup>d</sup> = Five case reports of hepatotoxicity published (as of 2016). No cases in a high-dose (150&nbsp;mg/day) 4,000-patient trial (incidence of <0.03%).<br />''Sources:'' <ref name="pmid12231039">{{cite journal | vauthors = Mcleod DG | title = Emerging role of adjuvant hormonal therapy | journal = Urology | volume = 60 | issue = 3 Suppl 1 | pages = 13–20; discussion 21 | date = September 2002 | pmid = 12231039 | doi = 10.1016/S0090-4295(02)01562-5 | url = }}</ref><ref name="PMS-Bicalutamide-Label">https://pdf.hres.ca/dpd_pm/00009096.PDF</ref><ref name="pmid12353966">{{cite journal | vauthors = Bennett CL, Raisch DW, Sartor O | title = Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect |journal=Annals of Internal Medicine | volume = 137 | issue = 7 | pages = 625 | date = October 2002 | pmid = 12353966 | doi = 10.7326/0003-4819-137-7-200210010-00029 | quote = An estimated 0.77% of the 6,480 nilutamide-treated patients, 0.04% of the 41,700 flutamide-treated patients, and 0.01% of the 86,800 bicalutamide-treated patients developed pneumonitis during the study period.}}</ref><ref name="Molina ManceroPicón2016">{{cite journal | last1 = Molina Mancero | first1 = Guillermo | last2 = Picón | first2 = Xavier | last3 = Di Tullio | first3 = Fernando | last4 = Ernst | first4 = Glenda | last5 = Dezanzo | first5 = Pablo | last6 = Salvado | first6 = Alejandro | last7 = Chertcoff | first7 = Julio F | title = Neumonía intersticial inducida por bloqueo androgénico máximo como tratamiento de cáncer de próstata avanzado | trans-title = Fatal interstitial lung disease associated with maximum androgen blockade. Report of one case | journal = Revista médica de Chile | volume = 144 | issue = 10 | year = 2016 | pages = 1356–1359 | issn = 0034-9887 | doi = 10.4067/S0034-98872016001000017}}</ref><ref name="pmid26663090">{{cite journal | vauthors = Lee K, Oda Y, Sakaguchi M, Yamamoto A, Nishigori C | title = Drug-induced photosensitivity to bicalutamide - case report and review of the literature | journal = Photodermatol Photoimmunol Photomed | volume = 32 | issue = 3 | pages = 161–4 | date = May 2016 | pmid = 26663090 | doi = 10.1111/phpp.12230 | url = }}</ref><ref name="pmid27099451">{{cite journal | vauthors = Yun GY, Kim SH, Kim SW, Joo JS, Kim JS, Lee ES, Lee BS, Kang SH, Moon HS, Sung JK, Lee HY, Kim KH | title = Atypical onset of bicalutamide-induced liver injury | journal = World J. Gastroenterol. | volume = 22 | issue = 15 | pages = 4062–5 | date = April 2016 | pmid = 27099451 | pmc = 4823258 | doi = 10.3748/wjg.v22.i15.4062 | url = }}</ref><ref name="pmid12603397">{{cite journal | vauthors = Anderson J | title = The role of antiandrogen monotherapy in the treatment of prostate cancer | journal = BJU Int. | volume = 91 | issue = 5 | pages = 455–61 | date = March 2003 | pmid = 12603397 | doi = 10.1046/j.1464-410X.2003.04026.x | url = }}</ref>}}
+
| colspan="3" style="width: 1px;" | {{Hidden | <noinclude>expanded = true |</noinclude> header = Footnotes and sources | content = <sup>a</sup> = Incidence of breast changes of up to 80 to 90%. Mild-to-moderate in 90% of cases. Incidence greatly decreased in combination with castration.<br /><sup>b</sup> = Elevated liver enzymes rarely severe and usually transient, resolving or improving with continued therapy or with discontinuation. Incidence of 3.4% relative to 1.9% for placebo in a high-dose (150&nbsp;mg/day) 4,000-patient trial.<br /><sup>c</sup> = Six case reports of interstitial lung disease published (as of 2016). Incidence of 0.01% (12 patients) in an 87,000-patient cohort.<br /><sup>d</sup> = Six case reports of hepatotoxicity published (as of 2018). No cases in a high-dose (150&nbsp;mg/day) 4,000-patient trial (suggesting incidence of <0.03%).<br />''Sources:'' <ref name="pmid12231039">{{cite journal | vauthors = Mcleod DG | title = Emerging role of adjuvant hormonal therapy | journal = Urology | volume = 60 | issue = 3 Suppl 1 | pages = 13–20; discussion 21 | date = September 2002 | pmid = 12231039 | doi = 10.1016/S0090-4295(02)01562-5 | url = }}</ref><ref name="PMS-Bicalutamide-Label">https://pdf.hres.ca/dpd_pm/00009096.PDF</ref><ref name="pmid12353966">{{cite journal | vauthors = Bennett CL, Raisch DW, Sartor O | title = Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect |journal=Annals of Internal Medicine | volume = 137 | issue = 7 | pages = 625 | date = October 2002 | pmid = 12353966 | doi = 10.7326/0003-4819-137-7-200210010-00029 | quote = An estimated 0.77% of the 6,480 nilutamide-treated patients, 0.04% of the 41,700 flutamide-treated patients, and 0.01% of the 86,800 bicalutamide-treated patients developed pneumonitis during the study period.}}</ref><ref name="Molina ManceroPicón2016">{{cite journal | last1 = Molina Mancero | first1 = Guillermo | last2 = Picón | first2 = Xavier | last3 = Di Tullio | first3 = Fernando | last4 = Ernst | first4 = Glenda | last5 = Dezanzo | first5 = Pablo | last6 = Salvado | first6 = Alejandro | last7 = Chertcoff | first7 = Julio F | title = Neumonía intersticial inducida por bloqueo androgénico máximo como tratamiento de cáncer de próstata avanzado | trans-title = Fatal interstitial lung disease associated with maximum androgen blockade. Report of one case | journal = Revista médica de Chile | volume = 144 | issue = 10 | year = 2016 | pages = 1356–1359 | issn = 0034-9887 | doi = 10.4067/S0034-98872016001000017}}</ref><ref name="pmid26663090">{{cite journal | vauthors = Lee K, Oda Y, Sakaguchi M, Yamamoto A, Nishigori C | title = Drug-induced photosensitivity to bicalutamide - case report and review of the literature | journal = Photodermatol Photoimmunol Photomed | volume = 32 | issue = 3 | pages = 161–4 | date = May 2016 | pmid = 26663090 | doi = 10.1111/phpp.12230 | url = }}</ref><ref name="GretarsdottirBjornsdottir2018">{{cite journal | last1 = Gretarsdottir | first1 = Helga M. | last2 = Bjornsdottir | first2 = Elin | last3 = Bjornsson | first3 = Einar S. | title = Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect | journal = Case Reports in Gastroenterology | volume = 12 | issue = 2 | year = 2018 | pages = 266–270 | issn = 1662-0631 | doi = 10.1159/000485175}}</ref><ref name="pmid12603397">{{cite journal | vauthors = Anderson J | title = The role of antiandrogen monotherapy in the treatment of prostate cancer | journal = BJU Int. | volume = 91 | issue = 5 | pages = 455–61 | date = March 2003 | pmid = 12603397 | doi = 10.1046/j.1464-410X.2003.04026.x | url = }}</ref>}}
 
|}<!--
 
|}<!--
  

Revision as of 13:06, 13 November 2018

Major side effects of Template:No selflink alone

Frequency Class Side effect
Very common
(≥10%)
Reproductive system
and breast disorders
Breast tendernessa
Gynecomastiaa
Common
(≥1% and <10%)
General and psychiatric
disorders
Asthenia
Decreased libido
Erectile dysfunction
Hot flashes
Skin and subcutaneous
tissue disorders
Decreased body hair
Hepato-biliary disorders Elevated liver enzymesb
Uncommon
(≥0.1% and <1%)
Immune system disorders Hypersensitivity reactions,
including angioedema and hives
Rare (<0.1%)
and unknown
Respiratory, thoracic, and
mediastinal disorders
Interstitial lung diseasec
Skin and subcutaneous
tissue disorders
Sensitivity to light
Hepato-biliary disorders Liver toxicityd
Footnotes and sources
a = Incidence of breast changes of up to 80 to 90%. Mild-to-moderate in 90% of cases. Incidence greatly decreased in combination with castration.
b = Elevated liver enzymes rarely severe and usually transient, resolving or improving with continued therapy or with discontinuation. Incidence of 3.4% relative to 1.9% for placebo in a high-dose (150 mg/day) 4,000-patient trial.
c = Six case reports of interstitial lung disease published (as of 2016). Incidence of 0.01% (12 patients) in an 87,000-patient cohort.
d = Six case reports of hepatotoxicity published (as of 2018). No cases in a high-dose (150 mg/day) 4,000-patient trial (suggesting incidence of <0.03%).
Sources: [1][2][3][4][5][6][7]

References

  1. Mcleod DG (September 2002). "Emerging role of adjuvant hormonal therapy". Urology. 60 (3 Suppl 1): 13–20, discussion 21. doi:10.1016/S0090-4295(02)01562-5. PMID 12231039.
  2. https://pdf.hres.ca/dpd_pm/00009096.PDF
  3. Bennett CL, Raisch DW, Sartor O (October 2002). "Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect". Annals of Internal Medicine. 137 (7): 625. doi:10.7326/0003-4819-137-7-200210010-00029. PMID 12353966. An estimated 0.77% of the 6,480 nilutamide-treated patients, 0.04% of the 41,700 flutamide-treated patients, and 0.01% of the 86,800 bicalutamide-treated patients developed pneumonitis during the study period.
  4. Molina Mancero, Guillermo; Picón, Xavier; Di Tullio, Fernando; Ernst, Glenda; Dezanzo, Pablo; Salvado, Alejandro; Chertcoff, Julio F (2016). "Neumonía intersticial inducida por bloqueo androgénico máximo como tratamiento de cáncer de próstata avanzado" [Fatal interstitial lung disease associated with maximum androgen blockade. Report of one case]. Revista médica de Chile. 144 (10): 1356–1359. doi:10.4067/S0034-98872016001000017. ISSN 0034-9887.
  5. Lee K, Oda Y, Sakaguchi M, Yamamoto A, Nishigori C (May 2016). "Drug-induced photosensitivity to bicalutamide - case report and review of the literature". Photodermatol Photoimmunol Photomed. 32 (3): 161–4. doi:10.1111/phpp.12230. PMID 26663090.
  6. Gretarsdottir, Helga M.; Bjornsdottir, Elin; Bjornsson, Einar S. (2018). "Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect". Case Reports in Gastroenterology. 12 (2): 266–270. doi:10.1159/000485175. ISSN 1662-0631. no-break space character in |first1= at position 6 (help); no-break space character in |first3= at position 6 (help)
  7. Anderson J (March 2003). "The role of antiandrogen monotherapy in the treatment of prostate cancer". BJU Int. 91 (5): 455–61. doi:10.1046/j.1464-410X.2003.04026.x. PMID 12603397.